{"protocolSection":{"identificationModule":{"nctId":"NCT01900665","orgStudyIdInfo":{"id":"15136"},"secondaryIdInfos":[{"id":"H8A-MC-LZAX","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo","officialTitle":"Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo","acronym":"EXPEDITION 3"},"statusModule":{"statusVerifiedDate":"2019-09","overallStatus":"TERMINATED","whyStopped":"Solanezumab did not meet the study's primary endpoint.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-07"},"primaryCompletionDateStruct":{"date":"2016-10","type":"ACTUAL"},"completionDateStruct":{"date":"2017-02","type":"ACTUAL"},"studyFirstSubmitDate":"2013-07-12","studyFirstSubmitQcDate":"2013-07-12","studyFirstPostDateStruct":{"date":"2013-07-16","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-02-16","resultsFirstSubmitQcDate":"2018-02-16","resultsFirstPostDateStruct":{"date":"2018-03-14","type":"ACTUAL"},"dispFirstSubmitDate":"2016-12-21","dispFirstSubmitQcDate":"2016-12-21","dispFirstPostDateStruct":{"date":"2016-12-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-09-25","lastUpdatePostDateStruct":{"date":"2019-10-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD."},"conditionsModule":{"conditions":["Alzheimer's Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":2129,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Solanezumab","type":"EXPERIMENTAL","description":"Solanezumab 400 milligrams (mg) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.","interventionNames":["Drug: Solanezumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Solanezumab","description":"Administered Intravenously (IV)","armGroupLabels":["Solanezumab"],"otherNames":["LY2062430","A Beta Antibody"]},{"type":"DRUG","name":"Placebo","description":"Administered IV","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14)","description":"The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS that was used as the primary efficacy measure consists of 14 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze completion measures. The ADAS-Cog14 scale ranges from 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Alzheimer's Disease Cooperative Study- Instrumental Activities of Daily Living (ADCS-iADL)","description":"The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 11 Item Subscore (ADAS-Cog11)","description":"The cognitive subscale of ADAS (ADAS Cog11) consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Mini-Mental State Examination (MMSE)","description":"MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)","description":"The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Functional Activities Questionnaire (FAQ)","description":"FAQ is a 10-item, caregiver-based questionnaire and was administered to the study partner who was asked to rate the participant's ability to perform a variety of activities ranging from financial management, shopping, playing games, food preparation, traveling, keeping appointments, keeping track of current events, and understanding media. FAQ total score was calculated by adding the scores from each of the 10 items. A negative change indicated an improvement from baseline. FAQ Total Score is the sum of 10 items, ranging from 0 (best possible outcome) to 100 (worst possible outcome). LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB)","description":"CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Neuropsychiatric Inventory (NPI)","description":"NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite)","description":"Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation and healthcare resource utilization) was gathered from baseline and follow-up interviews. Reported number of hospitalizations per participant up to 76 weeks. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)","description":"Assesses QoL for AD: participant rates mood, relationships, memory, finances, physical condition, and overall QoL assessment. Each of 13 items, rated on a 4-point scale. Sum of items=total score (range: 13 to 52). Higher scores indicate greater QoL. Participant's primary caregiver asked to complete same measure. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in 5-Dimensional EuroQol Quality of Life Scale Proxy Version (EQ-5D Proxy)","description":"EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 3 severity levels: no, some, severe problems. Visual analog scale (VAS) assesses caregiver's impression of participant's health state; score ranges: 0 to 100 millimeter (mm). Lower scores=greater disease severity LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)","description":"Integrated Alzheimer's Disease Rating Scale is used to assess that solanezumab slows down the cognitive and functional decline associated with AD compared with placebo. iADRS is a simple linear combination of ADAS-Cog 13 or 14 and the ADCS-iADL. The scale ranges from 0 to 146, where lower scores indicate worse performance. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Percentage of Participants of Cognitive and Functional Responders","description":"Assess the proportion of participants who reach certain levels of cognitive and functional decline. Decline in cognition was defined as worsening from baseline by at least 6 or 9 points on the ADAS Cog14. If there is a cognitive decline of a specified cut-off or more at any time then the participant is considered a nonresponder. Functional nonresponders are participants who have not had any of the following at any time point: Clinically evident decline in ability to perform one or more basic ADL present at baseline; A clinically evident decline in ability to perform 20% or more of the instrumental ADL present at baseline; An increase in global CDR score of 1 point or more compared with baseline. A decline from no impairment to mild impairment (bADL, iADL is not considered clinically significant, but other declines of 1 or more points and any participant discontinuation within the first 6 months will be considered a non-responder.","timeFrame":"Baseline through Week 80"},{"measure":"Change From Baseline in Plasma Amyloid-Beta (Aβ) Species","description":"Concentration of amino acid peptide known as Aβ 1-42 in plasma. The change in plasma Aβ analytes after treatment were assessed separately for each plasma Aβ parameter. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI)","description":"The vMRI assessment of right and left hippocampal atrophy, is reported. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"},{"measure":"Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Solanezumab (LY2062430)","description":"Area Under the Concentration versus Time Curve was evaluated for Solanezumab.","timeFrame":"Visit 2 (Post-dose), Visit 5, 9, 15 (Pre-dose, Post-dose) and Visit 22 (Pre-dose): Pre-dose before the infusion, Post-dose 30 minutes End of Infusion"},{"measure":"Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan","description":"Florbetapir PET imaging was used to confirm the presence of amyloid pathology consistent with AD. Change from baseline was done to test the hypothesis that amyloid burden was reduced in participants in the treatment group. The change from baseline to the postbaseline visit of the composite summary standard uptake value ratio of florbetapir F18 was calculated. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit. The composite summary measure is an unweighted average of the 6 smaller regions (anterior cingulate, frontal medial orbital, parietal, posterior cingulate, precuneus, and temporal) normalized to whole cerebellum or subject-specific white matter.","timeFrame":"Baseline, Week 80"},{"measure":"Change From Baseline in Cerebrospinal Fluid (CSF) Aβ Levels","description":"Concentration of CSF parameters includes amino acid peptide known as Aβ 1-42 and Aβ 1-42. Analyses of these CSF biomarkers was conducted in a subset of participants (as an addendum to the protocol). The dependent variable for each CSF parameter was its change from baseline to endpoint. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","timeFrame":"Baseline, Week 80"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD\n* Has a Modified Hachinski Ischemia Scale score of less than or equal to 4\n* Has a Mini-Mental State Examination (MMSE) score of 20 through 26 at Screening visit\n* Has a Geriatric Depression Scale score of less than or equal to 6 (on the staff-administered short form)\n* Has had a magnetic resonance imaging (MRI) or computerized tomography (CT) scan performed within the past 2 years that has confirmed no findings inconsistent with a diagnosis of AD\n* Has a florbetapir positron emission tomography (PET) scan or cerebrospinal fluid (CSF) result consistent with the presence of amyloid pathology at screening\n\nExclusion Criteria:\n\n* Does not have a reliable caregiver who is in frequent contact with the participant (defined as at least 10 hours per week), will accompany the participant to the office and/or be available by telephone at designated times, and will monitor administration of prescribed medications\n* Meets National Institute of Neurological Disorders and Stroke/Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS/AIREN) criteria for vascular dementia\n* Has current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study; or has a life expectancy of \\<2 years\n* Has had a history within the last 5 years of a serious infectious disease affecting the brain or head trauma resulting in protracted loss of consciousness\n* Has a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen posttreatment\n* Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions\n* Has received acetylcholinesterase inhibitor (AChEIs), memantine and/or other AD therapy for less than 4 months or has less than 2 months of stable therapy on these treatments\n* Has received medications that affect the central nervous system (CNS), except treatments for AD, for less than 4 weeks\n* Has a history of chronic alcohol or drug abuse/dependence within the past 5 years\n* Has a Visit 1 MRI with results showing \\>4 Amyloid-related Imaging Abnormality (ARIA), -hemorrhage /hemosiderin deposition (ARIA-H) or presence of ARIA-E (edema/effusions)","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Xenoscience","city":"Phoenix","state":"Arizona","zip":"85004","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Banner Alzheimer's Institute","city":"Phoenix","state":"Arizona","zip":"85006","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"St Josephs Hospital and Medical Center","city":"Phoenix","state":"Arizona","zip":"85013","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"ANI Arizona Neurological Institute Research, PC","city":"Sun City","state":"Arizona","zip":"85351","country":"United States","geoPoint":{"lat":33.59754,"lon":-112.27182}},{"facility":"Banner Sun Health Research Institute","city":"Sun City","state":"Arizona","zip":"85351","country":"United States","geoPoint":{"lat":33.59754,"lon":-112.27182}},{"facility":"Center for Neurosciences","city":"Tucson","state":"Arizona","zip":"85718","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Arizona Health Sciences Center","city":"Tucson","state":"Arizona","zip":"85724","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"American Neuropsychiatric Research Institute, Inc","city":"Carson","state":"California","zip":"90746","country":"United States","geoPoint":{"lat":33.83141,"lon":-118.28202}},{"facility":"Neurology Center of North Orange County","city":"Fullerton","state":"California","zip":"92835","country":"United States","geoPoint":{"lat":33.87029,"lon":-117.92534}},{"facility":"Institute for Memory Impairment & Neurological Disorders","city":"Irvine","state":"California","zip":"92697","country":"United States","geoPoint":{"lat":33.66946,"lon":-117.82311}},{"facility":"University of California - San Diego","city":"La Jolla","state":"California","zip":"92037","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Senior Clinical Trials, Inc.","city":"Laguna Hills","state":"California","zip":"92653","country":"United States","geoPoint":{"lat":33.61252,"lon":-117.71283}},{"facility":"Torrance Clinical Research","city":"Lomita","state":"California","zip":"90717","country":"United States","geoPoint":{"lat":33.79224,"lon":-118.31507}},{"facility":"Collaborative Neuroscience Network - CNS","city":"Long Beach","state":"California","zip":"90806","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Apostle Clinical Trials, Inc","city":"Long Beach","state":"California","zip":"90813","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Univ of Southern California Medical Center","city":"Los Angeles","state":"California","zip":"90033","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"University of California Los Angeles School of Medicine","city":"Los Angeles","state":"California","zip":"90073","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"UCLA Medical Center","city":"Los Angeles","state":"California","zip":"90095","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Hoag Memorial Hospital","city":"Newport Beach","state":"California","zip":"92663","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"Pacific Neuroscience Medical Group","city":"Oxnard","state":"California","zip":"93030","country":"United States","geoPoint":{"lat":34.1975,"lon":-119.17705}},{"facility":"Anderson Clinical Research","city":"Redlands","state":"California","zip":"92374","country":"United States","geoPoint":{"lat":34.05557,"lon":-117.18254}},{"facility":"University of California, Davis - Health Systems","city":"Sacramento","state":"California","zip":"95817","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Artemis Institute for Clinical Research","city":"San Diego","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.71533,"lon":-117.15726}},{"facility":"Pacific Research Network Inc","city":"San Diego","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.71533,"lon":-117.15726}},{"facility":"Sharp Mesa Vista Hospital","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71533,"lon":-117.15726}},{"facility":"San Francisco Clinical Research Center","city":"San Francisco","state":"California","zip":"94109","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"University of California, San Francisco","city":"San Francisco","state":"California","zip":"94158","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Apex Research Institute","city":"Santa Ana","state":"California","zip":"92705","country":"United States","geoPoint":{"lat":33.74557,"lon":-117.86783}},{"facility":"St. Joseph Health","city":"Santa Rosa","state":"California","zip":"95403","country":"United States","geoPoint":{"lat":38.44047,"lon":-122.71443}},{"facility":"California Neuroscience Research","city":"Sherman Oaks","state":"California","zip":"91403","country":"United States","geoPoint":{"lat":34.15112,"lon":-118.44925}},{"facility":"Radiant Research","city":"Denver","state":"Colorado","zip":"80239","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Associated Neurologists of Southern Connecticut","city":"Fairfield","state":"Connecticut","zip":"06824","country":"United States","geoPoint":{"lat":41.14121,"lon":-73.26373}},{"facility":"Institute for Neurodegenerative Disorders","city":"New Haven","state":"Connecticut","zip":"06510","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Yale University School of Medicine","city":"New Haven","state":"Connecticut","zip":"06520-8020","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Research Center for Clinical Studies","city":"Norwalk","state":"Connecticut","zip":"06851","country":"United States","geoPoint":{"lat":41.1176,"lon":-73.4079}},{"facility":"Christiana Care Research Institute","city":"Newark","state":"Delaware","zip":"19713","country":"United States","geoPoint":{"lat":39.68372,"lon":-75.74966}},{"facility":"Georgetown University Hospital","city":"Washington","state":"District of Columbia","zip":"20057","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"facility":"Parkinson's Disease and Movement Disorders","city":"Boca Raton","state":"Florida","zip":"33486","country":"United States","geoPoint":{"lat":26.3669,"lon":-80.13033}},{"facility":"Quantum Laboratories","city":"Deerfield Beach","state":"Florida","zip":"33064","country":"United States","geoPoint":{"lat":26.31841,"lon":-80.09977}},{"facility":"Brain Matters Research","city":"Delray Beach","state":"Florida","zip":"33445","country":"United States","geoPoint":{"lat":26.46146,"lon":-80.07282}},{"facility":"Cohen Medical Associates P.A.","city":"Delray Beach","state":"Florida","zip":"33446","country":"United States","geoPoint":{"lat":26.46146,"lon":-80.07282}},{"facility":"Neuropsychiatric Research Center of Southwest Florida","city":"Fort Myers","state":"Florida","zip":"33912","country":"United States","geoPoint":{"lat":26.62168,"lon":-81.84059}},{"facility":"MD Clinical","city":"Hallandale Beach","state":"Florida","zip":"33009","country":"United States","geoPoint":{"lat":25.9812,"lon":-80.14838}},{"facility":"Galiz Research","city":"Hialeah","state":"Florida","zip":"33016","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Infinity Clinical Research . LLC","city":"Hollywood","state":"Florida","zip":"33021","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Jacksonville Center for Clinical Research","city":"Jacksonville","state":"Florida","zip":"32216","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Mayo Clinic of Jacksonville","city":"Jacksonville","state":"Florida","zip":"32224","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Miami Jewish Home and Hospital for the Aged","city":"Miami","state":"Florida","zip":"33137","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Renstar Medical Research","city":"Ocala","state":"Florida","zip":"34471","country":"United States","geoPoint":{"lat":29.1872,"lon":-82.14009}},{"facility":"Compass Research","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Neurology Clinical Research, Inc","city":"Sunrise","state":"Florida","zip":"33351-6637","country":"United States","geoPoint":{"lat":26.13397,"lon":-80.1131}},{"facility":"Axiom Research","city":"Tampa","state":"Florida","zip":"33609","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Stedman Clinical Trials","city":"Tampa","state":"Florida","zip":"33613","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"University of South Florida","city":"Tampa","state":"Florida","zip":"33613","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Premiere Research Institute at Palm Beach Neurology","city":"West Palm Beach","state":"Florida","zip":"33407","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"Atlanta Center of Medical Research","city":"Atlanta","state":"Georgia","zip":"30331","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Rush Alzheimer's Disease Center","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Alexian Brothers Medical Center","city":"Elk Grove Village","state":"Illinois","zip":"60007","country":"United States","geoPoint":{"lat":42.00392,"lon":-87.97035}},{"facility":"Indiana University School of Medicine","city":"Indianapolis","state":"Indiana","zip":"46202","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"University of Kansas Medical Center","city":"Kansas City","state":"Kansas","zip":"66160","country":"United States","geoPoint":{"lat":39.11417,"lon":-94.62746}},{"facility":"CTT Consultants","city":"Prairie Village","state":"Kansas","zip":"66206","country":"United States","geoPoint":{"lat":38.99167,"lon":-94.63357}},{"facility":"Heartland Research Associates","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Via Christi Regional Medical Center","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Baptist Physician's Lexington","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Private Office: J. Gary Booker","city":"Shreveport","state":"Louisiana","zip":"71104","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Maine Research Associates","city":"Auburn","state":"Maine","zip":"04210","country":"United States","geoPoint":{"lat":44.09785,"lon":-70.23117}},{"facility":"Maine Neurology","city":"Scarborough","state":"Maine","zip":"04074","country":"United States","geoPoint":{"lat":43.57814,"lon":-70.32172}},{"facility":"PharmaSite Research Inc","city":"Baltimore","state":"Maryland","zip":"21208","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"McLean Hospital","city":"Belmont","state":"Massachusetts","zip":"02478","country":"United States","geoPoint":{"lat":42.39593,"lon":-71.17867}},{"facility":"Brigham and Womens Hospital","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Boston University Medical Center","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"ActivMed Practices & Research, Inc","city":"Methuen","state":"Massachusetts","zip":"01844","country":"United States","geoPoint":{"lat":42.7262,"lon":-71.19089}},{"facility":"Boston Center for Memory","city":"Newton","state":"Massachusetts","zip":"02459","country":"United States","geoPoint":{"lat":42.33704,"lon":-71.20922}},{"facility":"Northern Michigan Neurology","city":"Traverse City","state":"Michigan","zip":"49684","country":"United States","geoPoint":{"lat":44.76306,"lon":-85.62063}},{"facility":"Hattiesburg Clinic","city":"Hattiesburg","state":"Mississippi","zip":"39401","country":"United States","geoPoint":{"lat":31.32712,"lon":-89.29034}},{"facility":"Univ of Nebraska Med Center","city":"Omaha","state":"Nebraska","zip":"68198","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Cleveland Clinic of Las Vegas","city":"Las Vegas","state":"Nevada","zip":"89106","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Las Vegas Radiology","city":"Las Vegas","state":"Nevada","zip":"89113","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"AdvanceMed Research","city":"Lawrenceville","state":"New Jersey","zip":"08648","country":"United States","geoPoint":{"lat":40.29733,"lon":-74.7296}},{"facility":"Albuquerque Neurosciences","city":"Albuquerque","state":"New Mexico","zip":"87109","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"Albany Medical College","city":"Albany","state":"New York","zip":"12206","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"Dent Neurological Institute","city":"Amherst","state":"New York","zip":"14226","country":"United States","geoPoint":{"lat":42.97839,"lon":-78.79976}},{"facility":"SPRI Clinical Trials, LLC.","city":"Brooklyn","state":"New York","zip":"11235","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"New York University Medical Center","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Mount Sinai Medical Center","city":"New York","state":"New York","zip":"10029-6574","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Columbia University Medical Center","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Richmond Behavorial Associates","city":"Staten Island","state":"New York","zip":"10312","country":"United States","geoPoint":{"lat":40.56233,"lon":-74.13986}},{"facility":"PMG Research of Charlotte, LLC","city":"Charlotte","state":"North Carolina","zip":"28203","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Behavioral Health Center Research","city":"Charlotte","state":"North Carolina","zip":"28211","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Guilford Neurologic Associates","city":"Greensboro","state":"North Carolina","zip":"27405","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"Wake Research Associates","city":"Raleigh","state":"North Carolina","zip":"27612","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"PMG Research of Winston-Salem, LLC","city":"Winston-Salem","state":"North Carolina","zip":"27103","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Valley Medical Research","city":"Centerville","state":"Ohio","zip":"45459","country":"United States","geoPoint":{"lat":39.62839,"lon":-84.15938}},{"facility":"Ohio State Univ College Of Medicine","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Neurology Specialists Inc.","city":"Dayton","state":"Ohio","zip":"45417","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"Insight Clinical Trials","city":"Shaker Heights","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.47394,"lon":-81.53707}},{"facility":"Red River Medical Center, LLC","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Cutting Edge Research Group","city":"Oklahoma City","state":"Oklahoma","zip":"73116","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"The Corvallis Clinic P.C.","city":"Corvallis","state":"Oregon","zip":"97330","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"facility":"Summit Research Network Inc","city":"Portland","state":"Oregon","zip":"97210","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Drexel University College of Medicine at EPPI","city":"Philadelphia","state":"Pennsylvania","zip":"19102","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"University of Pittsburgh Medical Center","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Rhode Island Mood & Memory Research Institute","city":"East Providence","state":"Rhode Island","zip":"02914","country":"United States","geoPoint":{"lat":41.81371,"lon":-71.37005}},{"facility":"Rhode Island Hospital","city":"Providence","state":"Rhode Island","zip":"02903","country":"United States","geoPoint":{"lat":41.82399,"lon":-71.41283}},{"facility":"Butler Hospital","city":"Providence","state":"Rhode Island","zip":"02906","country":"United States","geoPoint":{"lat":41.82399,"lon":-71.41283}},{"facility":"Roper St. Francis Healthcare","city":"Charleston","state":"South Carolina","zip":"29401","country":"United States","geoPoint":{"lat":32.77657,"lon":-79.93092}},{"facility":"Radiant Research","city":"Greer","state":"South Carolina","zip":"29651","country":"United States","geoPoint":{"lat":34.93873,"lon":-82.22706}},{"facility":"University Psychiatry Associates Avera Health","city":"Sioux Falls","state":"South Dakota","zip":"57105","country":"United States","geoPoint":{"lat":43.54997,"lon":-96.70033}},{"facility":"Quillen College of Medicine, East TN State University","city":"Johnson City","state":"Tennessee","zip":"37604","country":"United States","geoPoint":{"lat":36.31344,"lon":-82.35347}},{"facility":"Vanderbilt Univeristy School of Medicine","city":"Nashville","state":"Tennessee","zip":"37212","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Texas Neurology, PA","city":"Dallas","state":"Texas","zip":"75214","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"University of Texas Southwestern Medical Center at Dallas","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Diagnostic Research Group","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Radiant Research","city":"Murray","state":"Utah","zip":"84123","country":"United States","geoPoint":{"lat":40.66689,"lon":-111.88799}},{"facility":"University of Utah School of Medicine","city":"Salt Lake City","state":"Utah","zip":"84108","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"The Memory Clinic","city":"Bennington","state":"Vermont","zip":"05201","country":"United States","geoPoint":{"lat":42.87813,"lon":-73.19677}},{"facility":"National Clinical Research - Norfolk Inc","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"National Clinical Research - Richmond","city":"Richmond","state":"Virginia","zip":"23294","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Blue Ridge Research Center","city":"Roanoke","state":"Virginia","zip":"24018","country":"United States","geoPoint":{"lat":37.27097,"lon":-79.94143}},{"facility":"Veterans Affairs Puget Sound Health Care System","city":"Seattle","state":"Washington","zip":"98108","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Darlinghurst","state":"New South Wales","zip":"2010","country":"Australia","geoPoint":{"lat":-33.87939,"lon":151.21925}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"East Gosford","state":"New South Wales","zip":"2250","country":"Australia","geoPoint":{"lat":-33.43874,"lon":151.35338}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kogarah","state":"New South Wales","zip":"2217","country":"Australia","geoPoint":{"lat":-33.98333,"lon":151.11667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Box Hill","state":"Victoria","zip":"3128","country":"Australia","geoPoint":{"lat":-37.81887,"lon":145.12545}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Caulfield","state":"Victoria","zip":"3162","country":"Australia","geoPoint":{"lat":-37.88251,"lon":145.02288}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Fitzroy","state":"Victoria","zip":"3065","country":"Australia","geoPoint":{"lat":-37.79839,"lon":144.97833}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Heidelberg","state":"Victoria","zip":"3081","country":"Australia","geoPoint":{"lat":-37.75,"lon":145.06667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Subiaco","state":"Western Australia","zip":"06008","country":"Australia","geoPoint":{"lat":-31.9485,"lon":115.8268}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"London","state":"Ontario","zip":"N6C 5J1","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ottawa","state":"Ontario","zip":"K1N 5C8","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Peterborough","state":"Ontario","zip":"K9H2P4","country":"Canada","geoPoint":{"lat":44.30012,"lon":-78.31623}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toronto","state":"Ontario","zip":"M4G 3E8","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gatineau","state":"Quebec","zip":"J8T 8J1","country":"Canada","geoPoint":{"lat":45.47723,"lon":-75.70164}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Greenfield Park","state":"Quebec","country":"Canada","geoPoint":{"lat":45.48649,"lon":-73.46223}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sherbrooke","state":"Quebec","zip":"J1H1Z1","country":"Canada","geoPoint":{"lat":45.40008,"lon":-71.89908}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bron","zip":"69677","country":"France","geoPoint":{"lat":45.73333,"lon":4.91667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dijon","zip":"21033","country":"France","geoPoint":{"lat":47.31667,"lon":5.01667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63297,"lon":3.05858}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Marseille","zip":"13385","country":"France","geoPoint":{"lat":43.29551,"lon":5.38958}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Montpellier","zip":"34295","country":"France","geoPoint":{"lat":43.61092,"lon":3.87723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Paris","zip":"75013","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Reims","zip":"51092","country":"France","geoPoint":{"lat":49.25,"lon":4.03333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11198,"lon":-1.67429}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Strasbourg","zip":"67098","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Villeurbanne","zip":"69100","country":"France","geoPoint":{"lat":45.76667,"lon":4.88333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Berlin","zip":"12203","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Boeblingen","zip":"71034","country":"Germany"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hannover","zip":"30559","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mannheim","zip":"68165","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Munich","zip":"81675","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Siegen","zip":"57076","country":"Germany","geoPoint":{"lat":50.87481,"lon":8.02431}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ulm","zip":"89081","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Westerstede","zip":"26655","country":"Germany","geoPoint":{"lat":53.25682,"lon":7.92737}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Firenze","zip":"50134","country":"Italy","geoPoint":{"lat":43.77925,"lon":11.24626}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Genova","zip":"16128","country":"Italy","geoPoint":{"lat":44.40478,"lon":8.94438}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Milano","zip":"20122","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pisa","zip":"56126","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ponderano (BI)","zip":"13875","country":"Italy"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rome","zip":"00161","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Torino","zip":"10126","country":"Italy","geoPoint":{"lat":45.07049,"lon":7.68682}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Aichi","zip":"474-8511","country":"Japan","geoPoint":{"lat":32.51879,"lon":130.62158}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hyogo","zip":"670-0981","country":"Japan"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ibaraki","zip":"305-8576","country":"Japan","geoPoint":{"lat":34.81641,"lon":135.56828}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kanagawa","zip":"247-8533","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kobe","zip":"655-0037","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kyoto","zip":"616-8255","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Osaka","zip":"545-8586","country":"Japan","geoPoint":{"lat":34.69374,"lon":135.50218}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shizuoka","zip":"424-8636","country":"Japan","geoPoint":{"lat":34.98333,"lon":138.38333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tokushima","zip":"770-8503","country":"Japan","geoPoint":{"lat":34.06667,"lon":134.56667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tokyo","zip":"187-8551","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bydgoszcz","zip":"85-796","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Katowice","zip":"40-588","country":"Poland","geoPoint":{"lat":50.25841,"lon":19.02754}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Krakow","zip":"31-505","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sopot","zip":"81-824","country":"Poland","geoPoint":{"lat":54.4418,"lon":18.56003}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Szczecin","zip":"70-215","country":"Poland","geoPoint":{"lat":53.42894,"lon":14.55302}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Warsaw","zip":"01-813","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Barakaldo","zip":"48903","country":"Spain","geoPoint":{"lat":43.29639,"lon":-2.98813}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Barcelona","zip":"08014","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Getafe","zip":"28905","country":"Spain","geoPoint":{"lat":40.30571,"lon":-3.73295}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Guipuzcoa","zip":"20014","country":"Spain"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madrid","zip":"28006","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Plasencia","zip":"10600","country":"Spain","geoPoint":{"lat":40.03116,"lon":-6.08845}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Salt-Girona","zip":"17190","country":"Spain"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Jönköping","zip":"55185","country":"Sweden","geoPoint":{"lat":57.78145,"lon":14.15618}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Malmo","zip":"212 24","country":"Sweden","geoPoint":{"lat":55.60587,"lon":13.00073}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Molndal","zip":"431 41","country":"Sweden","geoPoint":{"lat":57.6554,"lon":12.01378}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Stockholm","zip":"14186","country":"Sweden","geoPoint":{"lat":59.33258,"lon":18.0649}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Umea","zip":"90185","country":"Sweden","geoPoint":{"lat":63.82842,"lon":20.25972}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bath","state":"Avon","zip":"BA1 3NG","country":"United Kingdom","geoPoint":{"lat":51.3751,"lon":-2.36172}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Plymouth","state":"Devon","zip":"PL6 8BX","country":"United Kingdom","geoPoint":{"lat":50.37153,"lon":-4.14305}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Crowborough","state":"East Sussex","zip":"TN6 1HB","country":"United Kingdom","geoPoint":{"lat":51.06098,"lon":0.16342}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Scotland","state":"Glasgow","zip":"G20 0XA","country":"United Kingdom"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Greater London","state":"London","zip":"W1G9JF","country":"United Kingdom"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Salford","state":"Manchester","zip":"M6 8HD","country":"United Kingdom","geoPoint":{"lat":53.48771,"lon":-2.29042}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Swindon","state":"Wiltshire","zip":"SN3 6BW","country":"United Kingdom","geoPoint":{"lat":51.55797,"lon":-1.78116}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Glasgow","zip":"G31 2ER","country":"United Kingdom","geoPoint":{"lat":55.86515,"lon":-4.25763}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Newcastle","zip":"NE4 5PL","country":"United Kingdom","geoPoint":{"lat":54.97328,"lon":-1.61396}}]},"referencesModule":{"references":[{"pmid":"29365294","type":"DERIVED","citation":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants were excluded after study enrollment,if PET imaging or CSF results did not show evidence of brain amyloid pathology,a screening MRI with results \\>4 ARIA-H(amyloid-related imaging abnormality-hemorrhage/hemosiderin deposition) or presence of ARIA-E(amyloid-related imaging abnormality-edema/effusions) and abnormal lab results were found.","groups":[{"id":"FG000","title":"Solanezumab","description":"Participants received Solanezumab 400 milligrams (mg)Intravenously (IV) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"FG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"periods":[{"title":"Placebo Controlled Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1057"},{"groupId":"FG001","numSubjects":"1072"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"1054"},{"groupId":"FG001","numSubjects":"1067"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"914"},{"groupId":"FG001","numSubjects":"908"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"143"},{"groupId":"FG001","numSubjects":"164"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"39"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"45"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Caregiver Decision","reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"41"}]},{"type":"Entry Criteria Not Met","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"9"}]}]},{"title":"Open Label Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Patients from Placebo Controlled Period were not required to enter into Open Label Period.","numSubjects":"881"},{"groupId":"FG001","comment":"Patients from Placebo Controlled Period were not required to enter into Open Label Period.","numSubjects":"859"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"881"},{"groupId":"FG001","numSubjects":"859"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Parent/Caregiver Decision","reasons":[{"groupId":"FG000","numSubjects":"33"},{"groupId":"FG001","numSubjects":"34"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"802"},{"groupId":"FG001","numSubjects":"765"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"28"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"BG001","title":"Placebo","description":"Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.\n\nPlacebo: Administered IV"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"72.69","spread":"7.814"},{"groupId":"BG001","value":"73.26","spread":"7.966"},{"groupId":"BG002","value":"72.98","spread":"7.894"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"600"},{"groupId":"BG001","value":"631"},{"groupId":"BG002","value":"1231"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"457"},{"groupId":"BG001","value":"441"},{"groupId":"BG002","value":"898"}]}]}]},{"title":"Ethnicity (NIH/OMB)","populationDescription":"All randomized participants who had baseline ethnicity data.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"970"},{"groupId":"BG001","value":"986"},{"groupId":"BG002","value":"1956"}]}],"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"98"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"921"},{"groupId":"BG001","value":"937"},{"groupId":"BG002","value":"1858"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","populationDescription":"All randomized participants who had baseline race data.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"970"},{"groupId":"BG001","value":"986"},{"groupId":"BG002","value":"1956"}]}],"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"146"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"33"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"878"},{"groupId":"BG001","value":"894"},{"groupId":"BG002","value":"1772"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Canada","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"127"}]}]},{"title":"Sweden","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"52"}]}]},{"title":"United States","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"537"},{"groupId":"BG001","value":"541"},{"groupId":"BG002","value":"1078"}]}]},{"title":"Japan","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"132"}]}]},{"title":"Poland","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"102"}]}]},{"title":"Italy","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"98"}]}]},{"title":"United Kingdom","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"89"}]}]},{"title":"Australia","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"68"}]}]},{"title":"France","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"173"}]}]},{"title":"Germany","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"96"}]}]},{"title":"Spain","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1057"},{"groupId":"BG001","value":"1072"},{"groupId":"BG002","value":"2129"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"114"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14)","description":"The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS that was used as the primary efficacy measure consists of 14 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze completion measures. The ADAS-Cog14 scale ranges from 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1053"},{"groupId":"OG001","value":"1067"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.65","spread":"0.355"},{"groupId":"OG001","value":"7.44","spread":"0.356"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.095","statisticalMethod":"Mixed Models Analysis","statisticalComment":"The Kenward-Roger approximation was used to estimate the denominator degrees of freedom.","paramType":"Mean Difference (Final Values)","paramValue":"-0.80","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.73","ciUpperLimit":"0.14"}]},{"type":"SECONDARY","title":"Change From Baseline in Alzheimer's Disease Cooperative Study- Instrumental Activities of Daily Living (ADCS-iADL)","description":"The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"908"},{"groupId":"OG001","value":"896"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.17","spread":"0.318"},{"groupId":"OG001","value":"-7.17","spread":"0.320"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive 11 Item Subscore (ADAS-Cog11)","description":"The cognitive subscale of ADAS (ADAS Cog11) consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1053"},{"groupId":"OG001","value":"1067"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.22","spread":"0.284"},{"groupId":"OG001","value":"5.90","spread":"0.285"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mini-Mental State Examination (MMSE)","description":"MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"893"},{"groupId":"OG001","value":"876"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.17","spread":"0.154"},{"groupId":"OG001","value":"-3.66","spread":"0.156"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL)","description":"The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"908"},{"groupId":"OG001","value":"897"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.42","spread":"0.386"},{"groupId":"OG001","value":"-8.77","spread":"0.387"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Activities Questionnaire (FAQ)","description":"FAQ is a 10-item, caregiver-based questionnaire and was administered to the study partner who was asked to rate the participant's ability to perform a variety of activities ranging from financial management, shopping, playing games, food preparation, traveling, keeping appointments, keeping track of current events, and understanding media. FAQ total score was calculated by adding the scores from each of the 10 items. A negative change indicated an improvement from baseline. FAQ Total Score is the sum of 10 items, ranging from 0 (best possible outcome) to 100 (worst possible outcome). LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"907"},{"groupId":"OG001","value":"892"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.17","spread":"0.212"},{"groupId":"OG001","value":"5.57","spread":"0.213"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB)","description":"CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"903"},{"groupId":"OG001","value":"895"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":"2.442"},{"groupId":"OG001","value":"2.23","spread":"2.692"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Neuropsychiatric Inventory (NPI)","description":"NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"909"},{"groupId":"OG001","value":"891"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.26","spread":"3.11"},{"groupId":"OG001","value":"0.382","spread":"0.387"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite)","description":"Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation and healthcare resource utilization) was gathered from baseline and follow-up interviews. Reported number of hospitalizations per participant up to 76 weeks. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Number of hospitalizations","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.\n\nPlacebo: Administered IV"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"909"},{"groupId":"OG001","value":"891"}]}],"classes":[{"title":"Basic ADL","categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.058"},{"groupId":"OG001","value":"0.35","spread":"0.058"}]}]},{"title":"Instrumental ADL","categories":[{"measurements":[{"groupId":"OG000","value":"0.55","spread":"0.099"},{"groupId":"OG001","value":"0.50","spread":"0.100"}]}]},{"title":"Sum of Basic and Instrumental ADL","categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"0.132"},{"groupId":"OG001","value":"0.86","spread":"0.134"}]}]},{"title":"Supervision","categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"0.125"},{"groupId":"OG001","value":"0.88","spread":"0.127"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)","description":"Assesses QoL for AD: participant rates mood, relationships, memory, finances, physical condition, and overall QoL assessment. Each of 13 items, rated on a 4-point scale. Sum of items=total score (range: 13 to 52). Higher scores indicate greater QoL. Participant's primary caregiver asked to complete same measure. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"853"},{"groupId":"OG001","value":"812"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.55","spread":"0.158"},{"groupId":"OG001","value":"-0.72","spread":"0.161"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 5-Dimensional EuroQol Quality of Life Scale Proxy Version (EQ-5D Proxy)","description":"EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 3 severity levels: no, some, severe problems. Visual analog scale (VAS) assesses caregiver's impression of participant's health state; score ranges: 0 to 100 millimeter (mm). Lower scores=greater disease severity LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mm","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"904"},{"groupId":"OG001","value":"892"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.10","spread":"0.556"},{"groupId":"OG001","value":"-2.61","spread":"0.562"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)","description":"Integrated Alzheimer's Disease Rating Scale is used to assess that solanezumab slows down the cognitive and functional decline associated with AD compared with placebo. iADRS is a simple linear combination of ADAS-Cog 13 or 14 and the ADCS-iADL. The scale ranges from 0 to 146, where lower scores indicate worse performance. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"903"},{"groupId":"OG001","value":"883"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.92","spread":"0.533"},{"groupId":"OG001","value":"-14.59","spread":"0.537"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants of Cognitive and Functional Responders","description":"Assess the proportion of participants who reach certain levels of cognitive and functional decline. Decline in cognition was defined as worsening from baseline by at least 6 or 9 points on the ADAS Cog14. If there is a cognitive decline of a specified cut-off or more at any time then the participant is considered a nonresponder. Functional nonresponders are participants who have not had any of the following at any time point: Clinically evident decline in ability to perform one or more basic ADL present at baseline; A clinically evident decline in ability to perform 20% or more of the instrumental ADL present at baseline; An increase in global CDR score of 1 point or more compared with baseline. A decline from no impairment to mild impairment (bADL, iADL is not considered clinically significant, but other declines of 1 or more points and any participant discontinuation within the first 6 months will be considered a non-responder.","populationDescription":"All randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline through Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1057"},{"groupId":"OG001","value":"1072"}]}],"classes":[{"title":"Cognitive Responders: Cut-off 6","categories":[{"measurements":[{"groupId":"OG000","value":"35.7"},{"groupId":"OG001","value":"35.3"}]}]},{"title":"Cognitive Responders: Cut-off 9","categories":[{"measurements":[{"groupId":"OG000","value":"55.2"},{"groupId":"OG001","value":"52.3"}]}]},{"title":"Functional Responders","categories":[{"measurements":[{"groupId":"OG000","value":"38.0"},{"groupId":"OG001","value":"36.8"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Plasma Amyloid-Beta (Aβ) Species","description":"Concentration of amino acid peptide known as Aβ 1-42 in plasma. The change in plasma Aβ analytes after treatment were assessed separately for each plasma Aβ parameter. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Picogram/milliliter","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1057"},{"groupId":"OG001","value":"1072"}]}],"classes":[{"title":"Modified amyloid beta 1-40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"841"},{"groupId":"OG001","value":"842"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"172754.36","spread":"1613.534"},{"groupId":"OG001","value":"262.98","spread":"1609.006"}]}]},{"title":"Modified amyloid beta1-42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"848"},{"groupId":"OG001","value":"840"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18485.26","spread":"104.913"},{"groupId":"OG001","value":"15.75","spread":"105.237"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI)","description":"The vMRI assessment of right and left hippocampal atrophy, is reported. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Cubic millimeter (mm^3)","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1057"},{"groupId":"OG001","value":"1072"}]}],"classes":[{"title":"Right hippocampal atrophy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"789"},{"groupId":"OG001","value":"771"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-145.7","spread":"75.42"},{"groupId":"OG001","value":"-154.1","spread":"81.06"}]}]},{"title":"Left hippocampal atrophy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"789"},{"groupId":"OG001","value":"771"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-142.3","spread":"74.27"},{"groupId":"OG001","value":"-146.3","spread":"78.04"}]}]},{"title":"Right hippocampal atrophy+Left hippocampal atrophy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"789"},{"groupId":"OG001","value":"771"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-288.0","spread":"135.19"},{"groupId":"OG001","value":"-300.4","spread":"138.52"}]}]},{"title":"Right entorhinal cortex atrophy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"789"},{"groupId":"OG001","value":"771"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-77.3","spread":"45.18"},{"groupId":"OG001","value":"-80.8","spread":"45.16"}]}]},{"title":"Left entorhinal cortex atrophy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"789"},{"groupId":"OG001","value":"771"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-91.6","spread":"47.60"},{"groupId":"OG001","value":"-95.2","spread":"53.46"}]}]},{"title":"Right+Left entorhinal cortex atrophy","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"789"},{"groupId":"OG001","value":"771"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-169.0","spread":"79.65"},{"groupId":"OG001","value":"-176.0","spread":"86.11"}]}]},{"title":"Atrophy of whole brain volume","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"786"},{"groupId":"OG001","value":"769"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-22725.6","spread":"11920.78"},{"groupId":"OG001","value":"-23500.5","spread":"12000.09"}]}]},{"title":"Enlargement of Ventricular volume","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"788"},{"groupId":"OG001","value":"770"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7055.4","spread":"4580.36"},{"groupId":"OG001","value":"7226.6","spread":"4545.73"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Solanezumab (LY2062430)","description":"Area Under the Concentration versus Time Curve was evaluated for Solanezumab.","populationDescription":"All randomized participants who received at least 1 dose of study medication (Solanezumab) with evaluable Solanezumab PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"milligram*hour per milliliter (mg*h/mL)","timeFrame":"Visit 2 (Post-dose), Visit 5, 9, 15 (Pre-dose, Post-dose) and Visit 22 (Pre-dose): Pre-dose before the infusion, Post-dose 30 minutes End of Infusion","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1044"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":"24.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan","description":"Florbetapir PET imaging was used to confirm the presence of amyloid pathology consistent with AD. Change from baseline was done to test the hypothesis that amyloid burden was reduced in participants in the treatment group. The change from baseline to the postbaseline visit of the composite summary standard uptake value ratio of florbetapir F18 was calculated. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit. The composite summary measure is an unweighted average of the 6 smaller regions (anterior cingulate, frontal medial orbital, parietal, posterior cingulate, precuneus, and temporal) normalized to whole cerebellum or subject-specific white matter.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"standard uptake value ratio","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"915"},{"groupId":"OG001","value":"924"}]}],"classes":[{"title":"Subject specific white matter corrected","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"805"},{"groupId":"OG001","value":"791"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.002"},{"groupId":"OG001","value":"0.02","spread":"0.002"}]}]},{"title":"Mean whole cerebellum corrected","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"805"},{"groupId":"OG001","value":"791"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.005"},{"groupId":"OG001","value":"0.00","spread":"0.005"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Cerebrospinal Fluid (CSF) Aβ Levels","description":"Concentration of CSF parameters includes amino acid peptide known as Aβ 1-42 and Aβ 1-42. Analyses of these CSF biomarkers was conducted in a subset of participants (as an addendum to the protocol). The dependent variable for each CSF parameter was its change from baseline to endpoint. LS Mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had baseline and post baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"picogram/milliliter","timeFrame":"Baseline, Week 80","groups":[{"id":"OG000","title":"Solanezumab","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks."},{"id":"OG001","title":"Placebo","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1057"},{"groupId":"OG001","value":"1072"}]}],"classes":[{"title":"Free amyloid beta 1-42, CSF","categories":[{"measurements":[{"groupId":"OG000","value":"-37.33","spread":"7.507"},{"groupId":"OG001","value":"-9.27","spread":"8.175"}]}]},{"title":"Modified amyloid beta 1-42, CSF","categories":[{"measurements":[{"groupId":"OG000","value":"315.69","spread":"42.620"},{"groupId":"OG001","value":"-107.91","spread":"42.907"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up To 80 Weeks","description":"All randomized participants who received at least 1 dose of study drug.","eventGroups":[{"id":"EG000","title":"Solanezumab: Double-Blind Phase","description":"Participants received Solanezumab 400 mg IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who completed the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.","seriousNumAffected":175,"seriousNumAtRisk":1054,"otherNumAffected":536,"otherNumAtRisk":1054},{"id":"EG001","title":"Placebo: Double-Blind Phase","description":"Participants received Placebo IV every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.","seriousNumAffected":203,"seriousNumAtRisk":1067,"otherNumAffected":530,"otherNumAtRisk":1067},{"id":"EG002","title":"Solanezumab: Open Label","description":"Participants who complete 80 weeks treatment/assessment of the double-blind period were entered into open-label period. Participants received Solanezumab 400 mg IV every 4 weeks for 180 weeks with an additional 4 weeks of assessments.","seriousNumAffected":102,"seriousNumAtRisk":879,"otherNumAffected":255,"otherNumAtRisk":879},{"id":"EG003","title":"Placebo: Open Label","description":"Participants who complete 80 weeks treatment/assessment of the double-blind period were entered into open-label period. Participants received Placebo IV every 4 weeks for 180 weeks with an additional 4 weeks of assessments.","seriousNumAffected":114,"seriousNumAtRisk":856,"otherNumAffected":260,"otherNumAtRisk":856}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Adams-stokes syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Aortic valve stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Arrhythmia supraventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1054},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":1067},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":879},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":856}]},{"term":"Atrioventricular block","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Atrioventricular block complete","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Atrioventricular block second degree","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":856}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":856}]},{"term":"Sinus node dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Toxic nodular goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Open angle glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Colitis ulcerative","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Duodenal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Hernial eventration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Intestinal polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Mallory-weiss syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Oesophageal rupture","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Peptic ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Rectal prolapse","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Retroperitoneal haematoma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":1054},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Stent-graft endoleak","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Systemic inflammatory response syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Gallbladder perforation","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Jaundice cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Portal vein thrombosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Abdominal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Atypical mycobacterial pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Atypical pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Bacterial sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Chronic sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Clostridium difficile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Escherichia sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Extradural abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Furuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Hepatitis e","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Intervertebral discitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Meningoencephalitis herpetic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Oesophageal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Ophthalmic herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Orchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":455},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":440},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":378},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":348}]},{"term":"Osteomyelitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Paraspinal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Pelvic abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":1054},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":1067},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":879},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":856}]},{"term":"Pneumonia influenzal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":856}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Alcohol poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Arthropod sting","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Chest injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Clavicle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Coronary vascular graft occlusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":24,"numAtRisk":1054},{"groupId":"EG001","numEvents":27,"numAffected":24,"numAtRisk":1067},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":879},{"groupId":"EG003","numEvents":12,"numAffected":12,"numAtRisk":856}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":1054},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1067},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Fibula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Fracture displacement","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Fractured coccyx","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Gastrointestinal stoma complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Gun shot wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":1054},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":1067},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":879},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":856}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Pelvic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Periprosthetic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Postoperative ileus","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Pubis fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Skull fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":856}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Sternal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Heart rate irregular","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Troponin t increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1054},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1067},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hypovolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Foot deformity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Lumbar spinal stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Spinal osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Spondylolisthesis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Tenosynovitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Abdominal neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"B-cell lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Benign small intestinal neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Bladder cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Bladder neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Breast cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cardiac myxoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Clear cell renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Colon adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Endometrial adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":599},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":627},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":501},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":508}]},{"term":"Glioblastoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Glioblastoma multiforme","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hepatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Intraductal proliferative breast lesion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Lip squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Lung adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Lung cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Malignant melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Malignant melanoma in situ","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Metastatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Oesophageal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Ovarian cancer stage iv","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":599},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":627},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":501},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":508}]},{"term":"Pancreatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Parathyroid tumour benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Plasma cell myeloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":455},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":440},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":378},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":348}]},{"term":"Prostate cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":455},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":440},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":378},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":348}]},{"term":"Rectal adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Renal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Squamous cell carcinoma of the tongue","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Transitional cell cancer of renal pelvis and ureter metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Uterine cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":599},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":627},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":501},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":508}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Basal ganglia infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cerebellar haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cerebellar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":856}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Coma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Dementia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Dementia alzheimer's type","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":856}]},{"term":"Dementia of the alzheimer's type, with delirium","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Embolic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Haemorrhagic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hypertensive encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Lacunar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Metabolic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Spinal epidural haematoma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Subarachnoid haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":1054},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":1067},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":879},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":856}]},{"term":"Thalamic infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Thalamus haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Thrombotic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Tonic convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Cephalhaematoma","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Device dislocation","organSystem":"Product Issues","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Abnormal behaviour","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Affective disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Aggression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Behavioural and psychiatric symptoms of dementia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Delusion","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":856}]},{"term":"Phobia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":1054},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":856}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Renal colic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Urinary bladder polyp","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":455},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":440},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":378},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":348}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":455},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":440},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":378},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":348}]},{"term":"Vulvar dysplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":599},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":627},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":501},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":508}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Organising pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Pharyngeal mass","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":1054},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":856}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Immobilisation prolonged","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Respite care","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Aortic stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":856}]},{"term":"Lymphoedema","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1067},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1054},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1067},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":879},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":856}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":86,"numAffected":76,"numAtRisk":1054},{"groupId":"EG001","numEvents":109,"numAffected":87,"numAtRisk":1067},{"groupId":"EG002","numEvents":24,"numAffected":23,"numAtRisk":879},{"groupId":"EG003","numEvents":18,"numAffected":17,"numAtRisk":856}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":69,"numAffected":54,"numAtRisk":1054},{"groupId":"EG001","numEvents":63,"numAffected":46,"numAtRisk":1067},{"groupId":"EG002","numEvents":32,"numAffected":23,"numAtRisk":879},{"groupId":"EG003","numEvents":18,"numAffected":15,"numAtRisk":856}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":114,"numAffected":89,"numAtRisk":1054},{"groupId":"EG001","numEvents":99,"numAffected":80,"numAtRisk":1067},{"groupId":"EG002","numEvents":31,"numAffected":29,"numAtRisk":879},{"groupId":"EG003","numEvents":36,"numAffected":32,"numAtRisk":856}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":74,"numAffected":64,"numAtRisk":1054},{"groupId":"EG001","numEvents":61,"numAffected":54,"numAtRisk":1067},{"groupId":"EG002","numEvents":25,"numAffected":23,"numAtRisk":879},{"groupId":"EG003","numEvents":23,"numAffected":21,"numAtRisk":856}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":79,"numAffected":58,"numAtRisk":1054},{"groupId":"EG001","numEvents":103,"numAffected":72,"numAtRisk":1067},{"groupId":"EG002","numEvents":47,"numAffected":38,"numAtRisk":879},{"groupId":"EG003","numEvents":46,"numAffected":36,"numAtRisk":856}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":195,"numAffected":146,"numAtRisk":1054},{"groupId":"EG001","numEvents":207,"numAffected":144,"numAtRisk":1067},{"groupId":"EG002","numEvents":97,"numAffected":67,"numAtRisk":879},{"groupId":"EG003","numEvents":109,"numAffected":80,"numAtRisk":856}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":44,"numAtRisk":1054},{"groupId":"EG001","numEvents":62,"numAffected":56,"numAtRisk":1067},{"groupId":"EG002","numEvents":23,"numAffected":21,"numAtRisk":879},{"groupId":"EG003","numEvents":22,"numAffected":22,"numAtRisk":856}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":70,"numAffected":63,"numAtRisk":1054},{"groupId":"EG001","numEvents":67,"numAffected":60,"numAtRisk":1067},{"groupId":"EG002","numEvents":26,"numAffected":26,"numAtRisk":879},{"groupId":"EG003","numEvents":23,"numAffected":23,"numAtRisk":856}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":61,"numAtRisk":1054},{"groupId":"EG001","numEvents":65,"numAffected":57,"numAtRisk":1067},{"groupId":"EG002","numEvents":24,"numAffected":23,"numAtRisk":879},{"groupId":"EG003","numEvents":31,"numAffected":29,"numAtRisk":856}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":96,"numAffected":86,"numAtRisk":1054},{"groupId":"EG001","numEvents":151,"numAffected":86,"numAtRisk":1067},{"groupId":"EG002","numEvents":34,"numAffected":28,"numAtRisk":879},{"groupId":"EG003","numEvents":42,"numAffected":29,"numAtRisk":856}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":54,"numAtRisk":1054},{"groupId":"EG001","numEvents":59,"numAffected":58,"numAtRisk":1067},{"groupId":"EG002","numEvents":18,"numAffected":15,"numAtRisk":879},{"groupId":"EG003","numEvents":17,"numAffected":17,"numAtRisk":856}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":62,"numAffected":60,"numAtRisk":1054},{"groupId":"EG001","numEvents":57,"numAffected":57,"numAtRisk":1067},{"groupId":"EG002","numEvents":18,"numAffected":18,"numAtRisk":879},{"groupId":"EG003","numEvents":20,"numAffected":20,"numAtRisk":856}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":53,"numAffected":44,"numAtRisk":1054},{"groupId":"EG001","numEvents":69,"numAffected":58,"numAtRisk":1067},{"groupId":"EG002","numEvents":27,"numAffected":25,"numAtRisk":879},{"groupId":"EG003","numEvents":22,"numAffected":18,"numAtRisk":856}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-07-25"},"conditionBrowseModule":{"meshes":[{"id":"D000544","term":"Alzheimer Disease"}],"ancestors":[{"id":"D003704","term":"Dementia"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D024801","term":"Tauopathies"},{"id":"D019636","term":"Neurodegenerative Diseases"},{"id":"D019965","term":"Neurocognitive Disorders"},{"id":"D001523","term":"Mental Disorders"}],"browseLeaves":[{"id":"M3885","name":"Alzheimer Disease","asFound":"Alzheimer's Disease","relevance":"HIGH"},{"id":"M20559","name":"Disease Progression","relevance":"LOW"},{"id":"M6904","name":"Dementia","relevance":"LOW"},{"id":"M5204","name":"Brain Diseases","relevance":"LOW"},{"id":"M5742","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M23002","name":"Tauopathies","relevance":"LOW"},{"id":"M21558","name":"Neurodegenerative Diseases","relevance":"LOW"},{"id":"M21836","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M14473","name":"Psychotic Disorders","relevance":"LOW"},{"id":"M4815","name":"Mental Disorders","relevance":"LOW"},{"id":"T2192","name":"Familial Alzheimer Disease","asFound":"Alzheimer's Disease","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M4225","name":"Antibodies","relevance":"LOW"},{"id":"M10184","name":"Immunoglobulins","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}